With the acceleration of China's aging process, the continuous rise in the number of patients with chronic diseases such as end-stage renal disease (ESRD), and the expansion of medical insurance coverage, the blood purification products market is entering a period of rapid development. As an important means for severe illness treatment and chronic disease management, the demand for core products of blood purification technology is steadily growing. Policy support, technological iteration, and other factors are further driving industry expansion.
If you have further research needs on the Chinese pharmaceutical market, please contact us:
Mr. Mao from Frost & Sullivan
Tel: (+86) 159-2139-6033
E-mail: fred.mao@frostchina.com
